Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07347444 | Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma | not yet recruiting | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07320222 | CARE-Melanoma Trial(CARE-Melanoma) | not yet recruiting | Phase 1 | 30 | McMaster UniversityOTHER | 0 | Jan 6, 2026 |
| clinicaltrials |
| NCT07293598 | Investigation of the ROle of faT and inflAmmaTory Cells in mElanoma(ROTATE) | not yet recruiting | — | 20 | The Christie NHS Foundation TrustOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 40 | AccSalus Biosciences, Inc.INDUSTRY | 0 | Nov 28, 2025 | clinicaltrials |
| NCT07246759 | Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis(NEUTROFLOW) | not yet recruiting | — | 600 | OncoHost Ltd.INDUSTRY | 3 | Nov 24, 2025 | clinicaltrials |
| NCT07236528 | Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma | not yet recruiting | Phase 2 | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Nov 19, 2025 | clinicaltrials |
| NCT07114172 | Study of Melanoma-Resistant PET Monitoring Based on Key Rate-limiting Enzymes for Fatty Acid Metabolism in Healthy Volunteers | not yet recruiting | N/A | 15 | Xijing HospitalOTHER | 0 | Aug 11, 2025 | clinicaltrials |
| NCT07107178 | A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma | not yet recruiting | Phase 1 | 58 | Biotroy TherapeuticsINDUSTRY | 0 | Aug 6, 2025 | clinicaltrials |
| NCT07040436 | Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1(REVERT) | not yet recruiting | Phase 1 / Phase 2 | 41 | Oncodesign Precision MedicineINDUSTRY | 0 | Jun 27, 2025 | clinicaltrials |
| NCT07028008 | Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte in Patients With Refractory Melanoma Who Failed to Immune Checkpoint Inhibitors | not yet recruiting | N/A | 9 | Samsung Medical CenterOTHER | 0 | Jun 26, 2025 | clinicaltrials |
| NCT07004335 | Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study | not yet recruiting | Phase 4 | 40 | Hebei Medical University Fourth HospitalOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06976021 | Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy(INTROSPECTION) | not yet recruiting | Phase 2 | 60 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 0 | May 16, 2025 | clinicaltrials |
| NCT05275374 | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation(ENHANCE) | not yet recruiting | Phase 1 / Phase 2 | 221 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 0 | Apr 10, 2025 | clinicaltrials |
| NCT06756295 | A Phase I/ II Study of Fragmented Autoantigen Stimulated T-cell-immunotherapy Combined with Radiotherapy (FAST-CR)(FAST-CR) | not yet recruiting | Early Phase 1 | 154 | Fengming KongOTHER | 0 | Mar 12, 2025 | clinicaltrials |
| NCT06788665 | Investigation of the Performance of the Medical Device Dermalyser in Determining Melanoma Thickness Based on Dermoscopy Images(AI-DSII) | not yet recruiting | — | 900 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06785974 | Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis(SPIRAL) | not yet recruiting | Phase 4 | 140 | Erasmus Medical CenterOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06780397 | Clinical and Ultrasound Incidence of Rheumatologic Immune Related Adverse Events in Stage IIB-IV Melanoma Patients(Mel-Immuno-Reu) | not yet recruiting | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06710093 | Power of Liquid Biopsy Tracking in Immunotherapy Treated Stage IV Melanoma(PerceIVe) | not yet recruiting | — | 100 | Royal Marsden NHS Foundation TrustOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06661577 | An Observational Study Using The LumAssure Device In Participants Undergoing Assessment Of Skin Conditions. | not yet recruiting | — | 3,000 | University of Auckland, New ZealandOTHER | 1 | Oct 28, 2024 | clinicaltrials |
| NCT06566404 | Gene Expression Profiles and ctDNA for Risk Stratification in Patients With Melanoma(CORRESPOND) | not yet recruiting | — | 200 | European Institute of OncologyOTHER | 0 | Sep 23, 2024 | clinicaltrials |
| NCT06553781 | A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide in Second-line and Subsequent Treatment of Advanced Melanoma | not yet recruiting | N/A | 28 | Fudan UniversityOTHER | 0 | Aug 14, 2024 | clinicaltrials |
| NCT06500091 | TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors | not yet recruiting | Phase 2 | 54 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 15, 2024 | clinicaltrials |
| NCT06470880 | Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy(DyNAMIc) | not yet recruiting | Phase 2 | 40 | The Christie NHS Foundation TrustOTHER | 0 | Jun 24, 2024 | clinicaltrials |
| NCT06327698 | Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure | not yet recruiting | Phase 2 | 30 | Hunan Cancer HospitalOTHER | 0 | Mar 25, 2024 | clinicaltrials |
| NCT06212388 | Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma | not yet recruiting | Early Phase 1 | 10 | Xijing HospitalOTHER | 0 | Jan 25, 2024 | clinicaltrials |
| NCT06093594 | Investigating Participation Patterns Among Stage IV Melanoma Patients | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05539118 | Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma | not yet recruiting | Phase 1 / Phase 2 | 48 | Xijing HospitalOTHER | 1 | Sep 14, 2022 | clinicaltrials |
| NCT04622566 | Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma | not yet recruiting | Phase 2 | 26 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04477876 | Study of CD160, an Activating NK Cell Receptor, in Melanoma: a Potential Therapeutic Target?(NKCD160MEL) | not yet recruiting | — | 55 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jul 20, 2020 | clinicaltrials |
| NCT02498756 | Cytokine-induced Killer Study for Patients With Stage II Melanoma | not yet recruiting | Phase 2 | 300 | The First People's Hospital of ChangzhouOTHER | 0 | Jul 15, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Jan 16, 2026source: clinicaltrials